Immunic Inc. diskutieren
Immunic Inc.
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
1,29 €
-0,62 %
Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its price target raised by analysts at Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at B. Riley. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Mersana Therapeutics diskutieren